Mutant p53 gain-of-function in cancer.

By Moshe Oren, Varda Rotter. Cold Spring Harbor Perspectives in Biology, 2010

781 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. (2011, background): “This term refers to the acquisition of oncogenic properties by the mutant protein, compared with the mere inactivation of the protein.(18,19) Both the DN and GOF effects may play a significant role in the positive selection of missense mutations in TP53 during tumorigenesis.”
Mutant p53: one name, many proteins. (2012, background): “Until recently, the prevailing hypothesis to explain the observation of high levels of mutant p53 in tumors was that p53 mutation broke this feedback loop by rendering the p53 mutant protein incapable of transactivating MDM2 (Oren and Rotter 2010).”
TP53 mutations in human cancers: origins, consequences, and clinical use. (2010, background): “…such as interference with the p53-family proteins p63 and p73, interference with the ATM DNA repair pathway (Song et al. 2007), activation of genes normally unaffected or repressed by wildtype p53, interference with other transcription factors, and resistance to drugs (see Oren and Rotter 2010).”
Predicting the functional impact of protein mutations: application to cancer genomics (2011, background): “Although the biological effects of TP53 mutations in cancer are affected by a various posttranscriptional factors (56), direct measurements of transcriptional activity of mutant TP53 are very useful for assessment of the impact of TP53 mutations in cancer.”